Rare Diseases
Conference Coverage
SCC survival remains poor in epidermolysis bullosa
LONDON – Median survival was 2.4 years in patients with generalized severe recessive dystrophic epidermolysis bullosa after a first diagnosis.
Photo Challenge
Chronic Diarrhea in an Adolescent Girl With a Genetic Skin Condition
A 17-year-old adolescent girl visited our clinic to establish care for her genetic skin condition. She exhibited red scaly plaques and patches...
Conference Coverage
Prioritize oral health in children with DEB
LONDON – While it may not be the first thing on the minds of families of children with DEB, it is important to consider oral health early to...
Conference Coverage
Target plantar keratoderma when managing ‘mild’ EBS
LONDON – Plantar keratoderma was associated with a vicious circle of pain, reduced mobility, subsequent weight gain, and further foot problems.
Conference Coverage
Hand deformity happens early in children with dystrophic epidermolysis bullosa
LONDON – By age 12, all children with recessive dystrophic epidermolysis bullosa had moderate to severe hand deformity with reduced finger flexion...
Latest News
Epidermolysis bullosa classification criteria refined and ready
LONDON – Epidermolysis bullosa classification criteria have been reworked and are a further step in understanding the rare genetic disease.
Conference Coverage
Psoriasis ointment helped with itch, healing in phase 2 EB study
LONDON – Low-dose calcipotriol ointment significantly improved wound healing and itch in people with epidermolysis bullosa in a pilot study.
Conference Coverage
Losartan showing promise in pediatric epidermolysis bullosa trial
LONDON – No safety concerns have been seen so far with the antihypertensive drug losartan in children with the skin blistering disease.
Conference Coverage
High cost of wound dressings for epidermolysis bullosa highlighted
LONDON – Dressing and bandage costs were highest for study participants with the generalized severe subtype, at about $112,450 per patient...
From the Journals
Most epidermolysis bullosa patients turn to topical antimicrobials
.
News
FDA approves first treatment for advanced epithelioid sarcoma
Tazemetostat earns accelerated approval for the treatment of patients aged 16 years and older with metastatic or locally advanced epithelioid...